Lumida
/AKBA
⌘K
Akebia Therapeutics Inc

Akebia Therapeutics Inc

AKBA
$0.95USD+0.55%+0.01 today

MARKET CAP

263.7M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$3

AI Summary

Stalk
StalkMedium

Despite the long-term downtrend, AKBA’s early Stage 1 base and the Bullish Pivot Point suggest upward mean-reversion potential. Price is currently extended above the rising short EMAs and testing resistance at the 50-day SMA without clear exhaustion, so execution should be deferred. We will await a pullback into the 9/21 EMA support zone near the base lows before initiating participation.

  • Vafcio net product revenue rose 60% YoY to $21.3M in Q2 2026
  • Patient enrollment grew 41% QoQ to over 10,500 active users
  • Total revenues fell 21% YoY to $49.1M, driven by Arixia declines
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$211.7M$292.5M$194.6M$160.2M$236.2M
YoY %-28.2%+38.2%-33.5%-17.7%+47.5%
P / Sales1.8x0.4x1.2x2.5x1.8x
EV / Sales3.2x1.3x2.4x3.9x2.4x
Gross Profit, Adj.$61.0M$206.9M$120.5M$97.0M$196.7M
YoY %+3426.7%+239.3%-41.8%-19.5%+102.8%
Margin %28.8%70.7%61.9%60.6%83.3%
EV / Gross Profit11.2x1.8x3.9x6.4x2.9x
EBITDA, Adj.$-226.5M$-27.1M$-8.4M$-12.9M$24.8M
YoY %+34.0%+88.0%+68.9%-52.8%+291.9%
Margin %-107.0%-9.3%-4.3%-8.1%10.5%
EV / EBITDA-3.0x-13.8x-55.3x-47.9x23.1x
EBIT$-264.5M$-80.8M$-46.3M$-50.5M$23.5M
YoY %+30.0%+69.5%+42.7%-9.1%+146.6%
Margin %-125.0%-27.6%-23.8%-31.5%9.9%
EV / EBIT-2.6x-4.6x-10.1x-12.3x24.4x
Net Income$-282.0M$-94.2M$-51.9M$-69.4M$-5.3M
YoY %+26.7%+66.6%+44.9%-33.7%+92.3%
Net Margin-133.3%-32.2%-26.7%-43.3%-2.3%
EPS (GAAP)-$1.70-$0.52-$0.28-$0.33-$0.02
YoY %+38.8%+69.4%+46.2%-17.9%+93.9%